VFA
ACRS icon

Valeo Financial Advisors’s Aclaris Therapeutics ACRS Stock Holding History

Valeo Financial Advisors’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-27,540
Closed -$82.9K – 758
2025
Q4 		$82.9K Buy
+27,540
New +$69.6K ﹤0.01% 796

Other funds holding ACRS

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Valeo Financial Advisors's ACRS Position: Q1 2026 in Review

Valeo Financial Advisors sold out of Aclaris Therapeutics (ACRS) in Q1 2026, closing a stake of 27,540 shares — an estimated $82.9K sold.

Valeo Financial Advisors first reported a position in ACRS in Q4 2025 and held it in 1 quarter. The position peaked at $82.9K in Q4 2025. 136 funds tracked by Wall St. Rank hold ACRS as of Q1 2026.

  • Valeo Financial Advisors reported no remaining Aclaris Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Valeo Financial Advisors sold 27,540 Aclaris Therapeutics shares in Q1 2026, an estimated $82.9K.
  • Valeo Financial Advisors first reported a position in Aclaris Therapeutics in Q4 2025 and held it in 1 quarter.
  • Valeo Financial Advisors's Aclaris Therapeutics position peaked at $82.9K in Q4 2025.
  • 136 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q1 2026.

Based on Valeo Financial Advisors's 13F filing for Q1 2026, filed 8 May 2026.